 HOLLISTON, Mass. , March 30, 2022 PRNewswire -- Biostage, Inc. OTCQB: BSTG Biostage or the Company, a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer conducted at the Mayo Clinic and published last August and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease including cancer, today announced that it will be hosting a conference call to discuss fourth quarter and full year financial results. 